Business
Mesoblast stumbles as FDA demands more evidence of drug effectiveness – Sydney Morning Herald
The listed biotech’s push to get its flagship product approved in the US has suffered a setback, as the US regulator asks for more evidence of its effectiveness…
The biotech, valued at $1.9 billion, has been striving for a decade to get remestemcel-L approved in the US market. It is also trialling the same product for treatment of coronavirus, in cases where patients are experiencing severe respiratory distress.
The prospect of the coronavirus treatment has sent shares rallying in recent months. In April, Mesoblast shares were sitting at $1.46 but were at $5.08 before going into the trading halt this week.
Chief executive Silviu Itescu said he believed…
-
Noosa News20 hours agoElectrify your vehicle, home or business at Noosa’s EV & Electrify Everything Expo
-
General24 hours agoVance downplays row between Trump, ’emotional guy’ Musk
-
General16 hours agoCanberra man accused of flashing and assaulting 12-year-old girl released on bail
-
Noosa News18 hours agoDrought pushes farmers’ mental health to the brink across southern Australia